Lv61
1626 积分 2022-02-25 加入
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
2天前
已完结
根治性前列腺切除术后生化复发的高危患者诊治共识
2天前
已完结
Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer
2天前
求助中
Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How
2天前
已完结
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial
2天前
已完结
Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial
27天前
已完结
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
2个月前
已完结
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
2个月前
已完结
596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
2个月前
已完结
Harnessing the potential of CD40 agonism in cancer therapy
2个月前
已完结
Synthesis and Cytotoxic Activity of Combretastatin A-4 and 2,3-Diphenyl-2H-indazole Hybrids
皖公网安备34019202002308
